NASDAQ:QNTM Quantum Biopharma Q3 2026 Earnings Results & Report $1.43 -0.09 (-5.66%) As of 02:42 PM Eastern This is a fair market value price provided by Massive. Learn more. Quantum Biopharma beat analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.06 versus the -$0.50 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeAfter Market Closes Quantum Biopharma EPS ResultsActual EPS-$0.06Consensus EPS -$0.50Beat/MissBeat by +$0.44One Year Ago EPSN/AEPS Beat Rate1 of last 8 quartersQuantum Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Quantum Biopharma Q3 2026 Earnings FAQ Did Quantum Biopharma beat earnings estimates for Q3 2026? Quantum Biopharma (NASDAQ:QNTM) reported earnings of -$0.06 per share for Q3 2026, beating the consensus estimate of -$0.50. The report was announced on Thursday, November 12, 2026. Quantum Biopharma Earnings HeadlinesQuantum Biopharma (NASDAQ:QNTM) Upgraded at Wall Street ZenNovember 17 at 2:17 AM | americanbankingnews.comQuantum BioPharma (NASDAQ: QNTM) Reports $12.22M in Cash and Digital Assets, Advances Lucid-MS Phase 2 TrialNovember 16 at 1:41 PM | markets.businessinsider.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 19 at 1:00 AM | Base Camp Trading (Ad)Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-UpNovember 13, 2026 | globenewswire.comQuantum BioPharma Reports Shareholder Approvals and C$80.86 Private PlacementNovember 12, 2026 | tipranks.comQuantum BioPharma (QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting ControlNovember 11, 2026 | finance.yahoo.comSee More Quantum Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email. Email Address About Quantum BiopharmaQuantum Biopharma (NASDAQ:QNTM) is a Canadian biopharmaceutical company focused on developing treatments for neurodegenerative and other challenging medical conditions. The company was formerly known as FSD Pharma and adopted its current name in 2024.Its lead research program is Lucid-MS, an investigational drug candidate being developed for multiple sclerosis. The company describes the program as targeting myelin degradation, a process associated with the disease. Lucid-MS is still under development and is not an approved treatment.Quantum BioPharma conducts its drug-development work through subsidiaries, including Lucid Psycheceuticals. Its activities are centered on research and development rather than marketing an established portfolio of approved medicines.View Quantum Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.